MacroGenics and Merck announce a collaboration to evaluate the combination of MacroGenics' margetuximab, with Merck's pembrolizumab in a Phase 1b/2 clinical trial in patients with gastric cancer
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Don’t see a project related to the catalyst you care about?